Doctors quested if they would use generics of Baraclude soon expired in patent

The so-called ‘Big 5’ treatment market, expired in patent this year, has attracted the industry. Among the Big 5, the patent of Lilly’s Alimta was expired for the first time on May this year, and Pfizer’s ‘Celebrex’ and Dong-A ST’s ‘Stillen’ were also expired in patent on June and July, respectively. Lilly’s ‘Cialis’ on September and BMS’s ‘Baraclude’ on October will face expiration soon.

The ...